• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新生儿干血斑中肌酸激酶-MM 浓度及其对杜氏肌营养不良症新生儿筛查的影响。

Creatine kinase-MM concentration in dried blood spots from newborns and implications for newborn screening for Duchenne muscular dystrophy.

机构信息

Division of Genetics, Wadsworth Center, New York State Department of Health, David Axelrod Institute, Albany, New York, USA.

出版信息

Muscle Nerve. 2022 Jun;65(6):652-658. doi: 10.1002/mus.27533. Epub 2022 Apr 6.

DOI:10.1002/mus.27533
PMID:35307847
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9322420/
Abstract

INTRODUCTION/AIMS: Creatine kinase-MM (CK-MM) is a marker of skeletal muscle damage. Detection of elevated levels of CK-MM in newborns can enable an early suspicion of the diagnosis of Duchenne muscular dystrophy (DMD) before symptom onset. Our aim was to investigate CK-MM levels in DMD-affected and unaffected newborns using an immunoassay that measures CK-MM concentration in dried blood spots collected for routine newborn screening.

METHODS

To validate the assay in our laboratory, CK-MM measurements and newborn demographic information were collected for 8584 de-identified specimens and 15 confirmed DMD patients. After analyzing validation data, CK-MM normal ranges were determined based on age of newborn at specimen collection. Subsequently, the assay was used to measure CK-MM concentration in 26 135 newborns as part of a consented pilot study to screen for DMD in New York State. Mean and median levels of CK-MM based on age of collection, in addition to the 2.5th, 50th, 97.5th, and 99.5th percentiles, were recalculated using the validation and screening data sets.

RESULTS

Median CK-MM within 1 hour of birth was 109 ng/mL, rose to a high of 499 ng/mL at 25 hours of age, and then declined to 200 ng/mL at 2 days of life. The median continued to decline more slowly and then stabilized at approximately 40 ng/mL at 1 week of life.

DISCUSSION

Because of the marked variability and elevated CK-MM levels observed within the first days of life, it is important to set multiple CK-MM age-related cut-offs when screening for DMD in newborns.

摘要

简介/目的:肌酸激酶-MM(CK-MM)是骨骼肌损伤的标志物。在症状出现前,检测新生儿 CK-MM 水平升高有助于早期怀疑杜氏肌营养不良症(DMD)的诊断。我们的目的是使用测量常规新生儿筛查采集的干血斑中 CK-MM 浓度的免疫分析法,检测 DMD 患儿和非 DMD 新生儿的 CK-MM 水平。

方法

为了在我们的实验室验证该检测方法,收集了 8584 份无身份信息的标本和 15 例确诊的 DMD 患者的 CK-MM 测量值和新生儿人口统计学信息。在分析验证数据后,根据标本采集时新生儿的年龄确定 CK-MM 正常范围。随后,该检测方法用于测量 26135 名新生儿的 CK-MM 浓度,作为在纽约州进行 DMD 筛查的同意试点研究的一部分。根据采集年龄,重新计算了 CK-MM 的均值和中位数水平,以及第 2.5、50、97.5 和 99.5 百分位数,使用验证和筛查数据集。

结果

出生后 1 小时内的 CK-MM 中位数为 109ng/mL,在 25 小时时升高至 499ng/mL,然后在 2 天龄时下降至 200ng/mL。中位数继续缓慢下降,然后在 1 周龄时稳定在约 40ng/mL。

讨论

由于在生命的最初几天内观察到明显的变异性和升高的 CK-MM 水平,因此在对新生儿进行 DMD 筛查时,设置多个与年龄相关的 CK-MM 截止值非常重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed4c/9322420/8853683a46bd/MUS-65-652-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed4c/9322420/30f71ccb5ccb/MUS-65-652-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed4c/9322420/8853683a46bd/MUS-65-652-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed4c/9322420/30f71ccb5ccb/MUS-65-652-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed4c/9322420/8853683a46bd/MUS-65-652-g002.jpg

相似文献

1
Creatine kinase-MM concentration in dried blood spots from newborns and implications for newborn screening for Duchenne muscular dystrophy.新生儿干血斑中肌酸激酶-MM 浓度及其对杜氏肌营养不良症新生儿筛查的影响。
Muscle Nerve. 2022 Jun;65(6):652-658. doi: 10.1002/mus.27533. Epub 2022 Apr 6.
2
Factors influencing creatine kinase-MM concentrations in newborns and implications for newborn screening for Duchenne muscular dystrophy.影响新生儿肌酸激酶-MM 浓度的因素及其对杜氏肌营养不良症新生儿筛查的影响。
Clin Biochem. 2023 Aug;118:110614. doi: 10.1016/j.clinbiochem.2023.110614. Epub 2023 Jul 19.
3
Two years of newborn screening for Duchenne muscular dystrophy as a part of the statewide Early Check research program in North Carolina.北卡罗来纳州全州范围内早期检查研究计划的新生儿杜氏肌营养不良症筛查两年。
Genet Med. 2024 Jan;26(1):101009. doi: 10.1016/j.gim.2023.101009. Epub 2023 Oct 17.
4
Characterization of a Blood Spot Creatine Kinase Skeletal Muscle Isoform Immunoassay for High-Throughput Newborn Screening of Duchenne Muscular Dystrophy.用于杜氏肌营养不良症高通量新生儿筛查的血斑肌酸激酶骨骼肌同工型免疫测定法的特征描述。
Clin Chem. 2017 Apr;63(4):908-914. doi: 10.1373/clinchem.2016.268425. Epub 2017 Feb 16.
5
Evidence-based path to newborn screening for Duchenne muscular dystrophy.基于证据的杜氏肌营养不良症新生儿筛查路径。
Ann Neurol. 2012 Mar;71(3):304-13. doi: 10.1002/ana.23528.
6
Age-Related Blood Levels of Creatine Kinase-MM in Newborns and Patients with Duchenne Muscular Dystrophy: Considerations for the Development of Newborn Screening Algorithms.新生儿及杜氏肌营养不良患者中与年龄相关的肌酸激酶-MM血液水平:新生儿筛查算法开发的考量因素
Int J Neonatal Screen. 2024 Jun 19;10(2):41. doi: 10.3390/ijns10020041.
7
Duchenne muscular dystrophy newborn screening: the first 50,000 newborns screened in Taiwan.杜氏肌营养不良症新生儿筛查:台湾 5 万名新生儿筛查的初步结果。
Neurol Sci. 2022 Jul;43(7):4563-4566. doi: 10.1007/s10072-022-06128-2. Epub 2022 May 13.
8
Newborn screening for Duchenne muscular dystrophy: A two-year pilot study.新生儿杜氏肌营养不良症筛查:一项为期两年的试点研究。
Ann Clin Transl Neurol. 2023 Aug;10(8):1383-1396. doi: 10.1002/acn3.51829. Epub 2023 Jun 23.
9
Newborn screening and genomic analysis of duchenne muscular dystrophy in Henan, China.中国河南杜氏肌营养不良症的新生儿筛查与基因组分析
Clin Chim Acta. 2023 Jan 15;539:90-96. doi: 10.1016/j.cca.2022.11.024. Epub 2022 Dec 11.
10
[Screening for Duchenne muscular dystrophy in newborns in the Ningxia region].[宁夏地区新生儿杜氏肌营养不良症筛查]
Zhongguo Dang Dai Er Ke Za Zhi. 2024 Mar 15;26(3):258-261. doi: 10.7499/j.issn.1008-8830.2309151.

引用本文的文献

1
Uncovering the Embryonic Origins of Duchenne Muscular Dystrophy.揭示杜氏肌营养不良症的胚胎起源。
WIREs Mech Dis. 2024 Nov-Dec;16(6):e1653. doi: 10.1002/wsbm.1653. Epub 2024 Oct 23.
2
Age-Related Blood Levels of Creatine Kinase-MM in Newborns and Patients with Duchenne Muscular Dystrophy: Considerations for the Development of Newborn Screening Algorithms.新生儿及杜氏肌营养不良患者中与年龄相关的肌酸激酶-MM血液水平:新生儿筛查算法开发的考量因素
Int J Neonatal Screen. 2024 Jun 19;10(2):41. doi: 10.3390/ijns10020041.
3
Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020-2023).

本文引用的文献

1
An Opportune Time for Newborn Screening in Duchenne Muscular Dystrophy.杜氏肌营养不良症新生儿筛查的适当时机。
JAMA Neurol. 2021 Aug 1;78(8):901-902. doi: 10.1001/jamaneurol.2021.1782.
2
The Impact of Seasonal Changes on Thyroxine and Thyroid-Stimulating Hormone in Newborns.季节变化对新生儿甲状腺素和促甲状腺激素的影响
Int J Neonatal Screen. 2021 Feb 3;7(1):8. doi: 10.3390/ijns7010008.
3
Duchenne Muscular Dystrophy Newborn Screening: Evaluation of a New GSP Neonatal Creatine Kinase-MM Kit in a US and Danish Population.
《2024年全球新生儿血斑筛查现状:2020 - 2023年近期活动综合回顾》
Int J Neonatal Screen. 2024 May 23;10(2):38. doi: 10.3390/ijns10020038.
4
Detection of mutation in a newborn with raised creatine kinase: A case report.一名肌酸激酶升高的新生儿中突变的检测:病例报告。
World J Clin Cases. 2024 May 16;12(14):2445-2450. doi: 10.12998/wjcc.v12.i14.2445.
5
The Early Care (0-3 Years) In Duchenne Muscular Dystrophy Meeting Report.《早发性护理(0-3 岁)在杜氏肌营养不良症会议报告》。
J Neuromuscul Dis. 2024;11(2):525-533. doi: 10.3233/JND-230180.
6
DAG1 haploinsufficiency is associated with sporadic and familial isolated or pauci-symptomatic hyperCKemia.DAG1单倍体不足与散发性和家族性孤立性或症状轻微的高肌酸激酶血症相关。
Eur J Hum Genet. 2024 Mar;32(3):342-349. doi: 10.1038/s41431-023-01516-4. Epub 2024 Jan 4.
7
Newborn screening for Duchenne muscular dystrophy: A two-year pilot study.新生儿杜氏肌营养不良症筛查:一项为期两年的试点研究。
Ann Clin Transl Neurol. 2023 Aug;10(8):1383-1396. doi: 10.1002/acn3.51829. Epub 2023 Jun 23.
8
Multi-Laboratory Evaluation of Prototype Dried Blood Spot Quality Control Materials for Creatine Kinase-MM Newborn Screening Assays.用于肌酸激酶-MM新生儿筛查检测的原型干血斑质量控制材料的多实验室评估
Int J Neonatal Screen. 2023 Feb 28;9(1):13. doi: 10.3390/ijns9010013.
9
A pilot study of newborn screening for Duchenne muscular dystrophy in Guangzhou.广州杜氏肌营养不良症新生儿筛查的一项试点研究。
Heliyon. 2022 Oct 14;8(10):e11071. doi: 10.1016/j.heliyon.2022.e11071. eCollection 2022 Oct.
10
Newborn Screening for Duchenne Muscular Dystrophy: First Year Results of a Population-Based Pilot.杜氏肌营养不良症的新生儿筛查:基于人群的试点项目第一年结果
Int J Neonatal Screen. 2022 Sep 22;8(4):50. doi: 10.3390/ijns8040050.
杜氏肌营养不良症新生儿筛查:在美国和丹麦人群中对一种新型干血斑新生儿肌酸激酶-MM试剂盒的评估。
Int J Neonatal Screen. 2019 Aug 27;5(3):27. doi: 10.3390/ijns5030027. eCollection 2019 Sep.
4
Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update.杜氏肌营养不良症的治疗策略:最新进展。
Genes (Basel). 2020 Jul 23;11(8):837. doi: 10.3390/genes11080837.
5
Is it the right time for an infant screening for Duchenne muscular dystrophy?现在是对婴儿进行杜氏肌营养不良症筛查的合适时机吗?
Neurol Sci. 2020 Jul;41(7):1677-1683. doi: 10.1007/s10072-020-04307-7. Epub 2020 Feb 28.
6
Therapeutic developments for Duchenne muscular dystrophy.杜氏肌营养不良症的治疗进展。
Nat Rev Neurol. 2019 Jul;15(7):373-386. doi: 10.1038/s41582-019-0203-3.
7
Newborn screening for Duchenne muscular dystrophy in China: follow-up diagnosis and subsequent treatment.中国对杜氏肌营养不良症的新生儿筛查:随访诊断及后续治疗。
World J Pediatr. 2017 Jun;13(3):197-201. doi: 10.1007/s12519-017-0036-3. Epub 2017 May 17.
8
Characterization of a Blood Spot Creatine Kinase Skeletal Muscle Isoform Immunoassay for High-Throughput Newborn Screening of Duchenne Muscular Dystrophy.用于杜氏肌营养不良症高通量新生儿筛查的血斑肌酸激酶骨骼肌同工型免疫测定法的特征描述。
Clin Chem. 2017 Apr;63(4):908-914. doi: 10.1373/clinchem.2016.268425. Epub 2017 Feb 16.
9
Identifying Non-Duchenne Muscular Dystrophy-Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review.鉴定既往杜氏肌营养不良症新生儿筛查方案中的非杜氏肌营养不良症阳性和假阴性结果:一项综述。
JAMA Neurol. 2016 Jan;73(1):111-6. doi: 10.1001/jamaneurol.2015.3537.
10
Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy.杜氏肌营养不良症中大规模血清蛋白生物标志物的发现
Proc Natl Acad Sci U S A. 2015 Jun 9;112(23):7153-8. doi: 10.1073/pnas.1507719112. Epub 2015 May 26.